| ZX-8177 / Zenshine Pharma |
NCT07310134 / CTR20254582: Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 80 | RoW | ZX-8177 | Nanjing Zenshine Pharmaceuticals | Indications: Advanced solid tumors | 11/26 | 12/26 | | |
CTR20254582: Phase I Clinical Study of ZX-8177 Tablets in Chinese Patients with Advanced Solid Tumors |
|
|
| Recruiting | 1 | 80 | China | 1. Chinese generic name: ZX-8177 tablets; English generic name: NA; Product name: NA; | Nanjing Zhengxiang Pharmaceutical Co., Ltd. | Indications: Advanced solid tumors | | | | |
| RBS2418 / Riboscience |
VISTA-1, NCT06824064: Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer |
|
|
| Recruiting | 2 | 150 | US, RoW | RBS2418, Placebo | Riboscience, LLC., Tam Anh Research Institute | Metastatic Colorectal Cancer, Advanced Colorectal Cancer | 12/27 | 12/27 | | |
NCT07175441: Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 220 | US | RBS2418, STRIDE (durvalumab + tremelimumab) | Riboscience, LLC. | Advanced Unresectable Hepatocellular Carcinoma | 04/27 | 08/27 | | |
NCT05270213: Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 164 | US | RBS2418, Pembrolizumab, Other approved anti-cancer therapy | Riboscience, LLC., Oncobay Clinical, Inc | Advanced Cancer | 04/27 | 12/27 | | |
| No Longer Available | N/A | | NA | RBS2418 | Riboscience, LLC., Dr. Bertrand Tuan | Expanded Access in Pancreatic Cancer | | | | |
| ISM033-154 / Insilico Medicine |
NCT06724042: Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors |
|
|
| Not yet recruiting | 1 | 159 | NA | ISM5939, Cisplatin, Docetaxel, Pembrolizumab | InSilico Medicine Hong Kong Limited | Advanced Solid Tumor, Metastatic Solid Tumor, Advanced and/or Metastatic Solid Tumors | 06/29 | 06/30 | | |
